News

An Israeli study is the first to administer 4 COVID-19 shots, but the boosted antibodies may still not be enough to prevent Omicron breakthrough infections.

In utilizing a modeling study, investigators estimated reductions in HIV incidence rates as well as PrEP usage rates and viral suppression across US cities over 10 years.

Eliminating the NS2 viral protein of Respiratory Syncytial Virus (RSV) helps the body to destroy the virus before it causes severe inflammation.

Study finds high false positive results with one batch of a rapid antigen test for SARS-CoV-2 but "very low" overall false positive rate.

A study adds to the growing list of trials assessing convalescent plasma in COVID-19 to yield mixed results.

People who vape with e-cigarettes and contract COVID-19 are significantly more likely to experience symptoms.

Telemedicine, virtual health consultations, may help increase access to care among under-resourced demographics during the COVID-19 pandemic.

A predictive tool, POC Advisor, has been developed to support faster diagnosis and intervention of this dangerous condition.

Implementation of CMS Severe Sepsis and Septic Shock Management Bundle did not reduce mortality rates in study of 114 hospitals.

Key signs and symptoms to help distinguish between the 2 respiratory illnesses.

Even if they did not experience severe symptoms, unvaccinated people who contract COVID-19 while pregnant are more likely to have poor birth outcomes.

Over 1 in 10 people may harbor infectious and transmissible COVID-19 virus after the recommended 10-day quarantine period.

A new study sought to address the association between a usual source of care and influenza vaccination rates among pregnant women.

COVID-19-infected people experiencing incarceration or homelessness in the US had higher rates of hospitalization and readmission than the general population.

Pfizer reports positive top-line results from a phase 3 study that simultaneously administered Prevnar 20 and its COVID-19 vaccine in older adults.

Investigators used an updated “kick and kill” strategy to expose and eliminate dormant infected cells in HIV-positive mice.

A model simulated the efficacy of the US’s COVID-19 vaccine rollout, measuring its correlation with reduced hospitalizations and deaths.

No influenza-related hospitalizations of children were found in a nationwide study of the impact of the COVID-19 pandemic on the 20/21 flu season.

There is a high level of engagement in HIV care observed among pregnant women, which displays a commitment to their health and wellbeing during their pregnancy, the study authors wrote.

During a continuation of a difficult time in our history, overwhelmed providers need to take a step back and find time for themselves to unwind and destress from COVID-19.

A study of children positive for COVID-19 found the overall risk of developing severe disease to be low, but risk factors included age, underlying chronic illness, and symptom duration.

Heterologous vaccine intervention (HVI), receiving immune-boosting vaccinations other than a COVID-19 shot, may alleviate COVID-19 case burdens.

Pfizer CEO Albert Bourla made the announcement in an interview.

The award given to the research institute by the state of Pennsylvania looks to delve deep in understanding vulnerable populations and taking some lessons away in addressing future potential pandemics.

Rising sea temperatures cause Vibrio species, bacteria linked to gastroenteritis, to be identified for the first time in UK waters.

The AIDS Clinical Trials Group (ACTG) is beginning stage 2 trials for Triplex, a novel vaccine for people living with HIV and cytomegalovirus (CMV).

Evidence for using antibody-rich convalescent plasma in early, outpatient treatment of COVID-19 is described as "solid."

By 2030, the US is targeting reducing the number of new HIV infections by 90 percent.

Breastfeeding babies safely receive COVID-19-neutralizing antibodies from their mRNA-vaccinated mothers.

Intravenous acyclovir shortened the duration of herpes simplex virus shedding among mechanically ventilated patients, a new study found, but the dose and duration tested weren’t sufficient to totally suppress oropharyngeal HSV reactivation and shedding.